PD-1、PD-L1肝移植术前治疗原发性肝癌对移植术后排斥反应的影响  

Effect of PD-1 and PD-L1 preoperative treatment on rejection after liver transplantation of liver cancer

作　　者：昔骜遥 吕涛[2] XI Aoyao;LÜTao(West China Clinical Medical College,Sichuan University,Chengdu 610041,P.R.China;Liver Transplant Center,West China Hospital,Sichuan University,Chengdu 610041,P.R.China)

机构地区：[1]四川大学华西临床医学院,成都610041 [2]四川大学华西医院肝移植中心,成都610041

出　　处：《中国普外基础与临床杂志》2023年第3期369-373,共5页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的总结目前程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)/程序性细胞死亡蛋白配体1(programmed cell death protein-ligand 1,PD-L1)抑制剂在肝癌肝移植术前应用的研究进展。方法收集关于PD-1/PD-L1抑制剂在肝癌肝移植术前应用的文献并进行综述。结果术前接受PD-1/PD-L1抑制剂治疗的晚期肝癌肝移植受体在术后排斥反应的发生率较低,且肝移植受体术中、术后常规应用激素及免疫耐受诱导治疗,可能降低PD-1/PD-L1抑制剂引起的排斥反应的发生率。结论术前使用PD-1/PD-L1抑制剂对晚期肝癌患者带来的收益大于其风险。Objective To summarize the research progress of programmed cell death protein 1(PD-1)/programmed cell death protein-ligand 1(PD-L1)inhibitors before liver transplantation of liver cancer.Method The literatures on the application of PD-1/PD-L1 inhibitors before liver transplantation of liver cancer were collected and reviewed.Results PD-1/PD-L1 inhibitors preoperatively treated liver transplantation recipients had a low incidence of postoperative rejection,and routine usage of hormone and immune tolerance induction therapy in liver transplantation recipients might reduce the incidence of rejection caused by PD-1/PD-L1 inhibitors.Conclusion Preoperative usage of PD-1/PD-L1 inhibitors have more benefits than risks for patients with advanced liver cancer.

关 键 词：程序性细胞死亡蛋白1 程序性细胞死亡蛋白配体1 免疫检查点抑制剂 肝癌 肝移植 免疫耐受 

分 类 号：R735.7[医药卫生—肿瘤]